Author

Megan Shelby

Institution: Lawrence Livermore National Laboratory

Observed institutions: Lawrence Livermore National Laboratory, Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center

OpenAlex ID: A5006855232

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

2023 · Ryan C Lynch, Chaitra S Ujjani, et al. · Blood · 40

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

2022 · Ryan C. Lynch, Christina Poh, et al. · Blood Advances · 18

Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

2021 · Ryan C. Lynch, Chaitra S. Ujjani, et al. · Blood · 14

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

2020 · Chaitra S. Ujjani, Catherine Lai, et al. · Blood · 8

Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.

2022 · Ryan C Lynch, Christina Poh, et al. · Journal of Clinical Oncology · 2

Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume

2022 · Ryan C. Lynch, Stefan K. Alig, et al. · Blood · 1

Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses

2026 · Sharon Jan, Christopher A Sumner, et al. · Antibody Therapeutics

Works count: 7

Citation count: 83

H-index: 4

I10-index: 3